125 related articles for article (PubMed ID: 31518680)
1. I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
Jia P; Wu Y; Du H; Yang L; Zhang Z; Ma T; Li S; Yuan S; Lu L; Zha X
Eur J Pharm Sci; 2019 Dec; 140():105072. PubMed ID: 31518680
[TBL] [Abstract][Full Text] [Related]
2. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
[TBL] [Abstract][Full Text] [Related]
3. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A
Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
5. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
Chaturvedi A; Goparaju R; Gupta C; Weder J; Klünemann T; Araujo Cruz MM; Kloos A; Goerlich K; Schottmann R; Othman B; Struys EA; Bähre H; Grote-Koska D; Brand K; Ganser A; Preller M; Heuser M
Leukemia; 2020 Feb; 34(2):416-426. PubMed ID: 31586149
[TBL] [Abstract][Full Text] [Related]
7. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Wu F; Jiang H; Zheng B; Kogiso M; Yao Y; Zhou C; Li XN; Song Y
J Med Chem; 2015 Sep; 58(17):6899-6908. PubMed ID: 26280302
[TBL] [Abstract][Full Text] [Related]
9. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
Verdura S; Cuyàs E; Lozano-Sánchez J; Bastidas-Velez C; Llorach-Parés L; Fernández-Arroyo S; Hernández-Aguilera A; Joven J; Nonell-Canals A; Bosch-Barrera J; Martin-Castillo B; Vellon L; Sanchez-Martinez M; Segura-Carretero A; Menendez JA
Carcinogenesis; 2019 Mar; 40(1):27-40. PubMed ID: 30428017
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
[TBL] [Abstract][Full Text] [Related]
11. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
Zhang N; Zheng B; Yao X; Huang X; Du J; Shen Y; Huang Z; Chen J; Lin Q; Lan W; Lin W; Ma W
Biochem Biophys Res Commun; 2021 Apr; 551():38-45. PubMed ID: 33714758
[TBL] [Abstract][Full Text] [Related]
13. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1.
Zheng M; Sun W; Gao S; Luan S; Li D; Chen R; Zhang Q; Chen L; Huang J; Li H
Oncotarget; 2017 Jul; 8(27):44255-44265. PubMed ID: 28498812
[TBL] [Abstract][Full Text] [Related]
14. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
16. Novel Insights for Inhibiting Mutant Heterodimer IDH1
Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
[TBL] [Abstract][Full Text] [Related]
17. Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
Urban DJ; Martinez NJ; Davis MI; Brimacombe KR; Cheff DM; Lee TD; Henderson MJ; Titus SA; Pragani R; Rohde JM; Liu L; Fang Y; Karavadhi S; Shah P; Lee OW; Wang A; McIver A; Zheng H; Wang X; Xu X; Jadhav A; Simeonov A; Shen M; Boxer MB; Hall MD
Sci Rep; 2017 Oct; 7(1):12758. PubMed ID: 28986582
[TBL] [Abstract][Full Text] [Related]
18. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
[TBL] [Abstract][Full Text] [Related]
19. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
